TELA Bio Announces Inducement Grants Under Nasdaq Listing

MALVERN, Pa., Oct. 28, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical expertise firm centered on offering revolutionary soft-tissue reconstruction options that optimize medical outcomes by prioritizing the preservation and restoration of the affected person’s personal anatomy, as we speak introduced that the Compensation Committee of the Board of Directors of TELA Bio authorized inducement grants of inventory choices to buy an combination of 54,600 shares of its frequent inventory and restricted inventory models protecting 7,500 shares of its frequent inventory to 11 newly-hired staff, with a grant date of October 26, 2022 (the “Grant Date”). The fairness awards have been granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a element of every particular person’s employment compensation and have been granted as an inducement materials to his or her acceptance of employment with TELA Bio.

The inventory choices have an train worth equal to $9.00 per share, the closing worth of TELA Bio’s frequent inventory as reported on the Nasdaq Global Market on the Grant Date. The inventory choices have a ten-year time period and vest over 4 years, with 25% of the shares underlying the inventory choice vesting on the primary anniversary of the Grant Date and the remaining 75% of the shares vesting in equal month-to-month installments over 36 months thereafter. The restricted inventory models will vest in equal annual installments over 4 years. The fairness awards are topic to every particular person’s continued service with TELA Bio by the relevant vesting dates.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical expertise firm centered on offering revolutionary applied sciences that optimize medical outcomes by prioritizing the preservation and restoration of the affected person’s personal anatomy. The Company is dedicated to offering surgeons with superior, economically efficient soft-tissue reconstruction options that leverage the affected person’s pure therapeutic response whereas minimizing long-term publicity to everlasting artificial supplies. For extra info, go to www.telabio.com.

Caution Regarding Forward-Looking Statements

This press launch comprises forward-looking statements throughout the which means of The Private Securities Litigation Reform Act of 1995. Words comparable to “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or comparable expressions, or statements concerning intent, perception, or present expectations are forward-looking statements and replicate the present beliefs of TELA Bio’s administration. These statements aren’t ensures of future efficiency and are topic to sure dangers, uncertainties and different components that might trigger precise outcomes and occasions to vary materially and adversely from these indicated by such forward-looking statements. These dangers and uncertainties are described extra totally within the “Risk Factors” part and elsewhere in our filings with the Securities and Exchange Commission and accessible at www.sec.gov, together with in our Annual Report on Form 10-Okay and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make on this announcement converse solely as of the date of this press launch, and TELA Bio assumes no obligation to replace forward-looking statements whether or not on account of new info, future occasions or in any other case after the date of this press launch, besides as required below relevant legislation.

Investor Contact Greg Chodaczek 332-895-3230
[email protected]